Abstract
Recombinant factor VIII has supplanted plasma-derived factor VIII for treatment of patients with hemophilia because it is not associated with the transmission of infectious agents. However, it does induce inhibitors (alloantibodies) in up to 35% of patients. To determine whether the risk for inhibitor development varies among recombinant factor VIII products, investigators in France analyzed data from 303 previously untreated boys with hemophilia …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
